GlobeNewswire Inc.T3·3mo ago
VCEL Vericel Corporation
XNAS
42.49
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VCEL
$42.49
—
Key stats
$42.49
- 52-Week Range
- $28.95 – $49.32
- YTD
- +19.32%
- IV Rank (30D)
- 75.11
- Straddle Price
- $6.65
- P/C Vol Ratio
- 0.33
- Market Cap
- $2.1B
- Open
- $43.02
- Day Range
- $42.23 – $43.02
- Volume
- 8,222
- Prev Close
- $42.91
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.99% |
| Beta vs SPY | 1.07 |
| Cost of Equity (CAPM) | 10.85% (VRP-adj) |
| WACC | 10.92% |
| Volatility Risk Premium | +52.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 3.4% |
| Rev. Growth (YoY, DCF input) | +14.7% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 6.6% |
| Book / Price | 16.7% |
| Gross Margin (TTM) | 74.6% |
| FCF Margin (TTM) | 20.1% |
| Debt / Equity | 0.00 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | +19.4% (reverse-DCF on current price) |
| SMA 50 | $40.62 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $41.11 |
| Bollinger Width / SMA20 | 26.4% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $2B |
Peers used for multiples: AMGN, BIIB, GILD, NTRA, REGN, RPRX, TGTX, VRTX
60-Day Conviction
78%
20-Day Fair Value
≈ by Nov 30, 2026
$42.81
α +1.1%
rank 52%
conviction
65%
40-Day Fair Value
≈ by Dec 29, 2026
$43.34
α +2.3%
rank 51%
conviction
74%
60-Day Fair Value
≈ by Jan 27, 2027
$43.58
α +2.9%
rank 48%
conviction
78%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $32.96 | 39% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $15.10 | 12% | median 29.2× · 6 peers |
| Peer EV/EBITDA | $16.97 | 12% | median 22.0× · 7 peers |
| Peer P/B | $75.64 | 12% | median 10.6× · 8 peers |
| Peer P/S | $55.79 | 12% | median 8.6× · 8 peers |
| Market Anchor (SMA50) | $40.62 | 14% | stability 18% (BB-width) |
| Options Expected (B-L 30d) | $44.16 | 0% | 5 strikes · skew +0.94 |
As of 2026-10-30 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $2.1B
- Employees
- 398
- List Date
- 1997-02-04
- CIK
- 0000887359
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- $0.06
- Headquarters
- Burlington, MA
- Homepage
- https://www.vcel.com
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 33.43% | -13.37% | 9.31% | 23.22% | 6.22% | 1.04% | 9.97% |
| Feb | 8.81% | 15.43% | 7.19% | 4.65% | -13.16% | -3.41% | 3.25% |
| Mar | 15.32% | -6.00% | -2.23% | 16.35% | -9.88% | -9.02% | 0.76% |
| Apr | 17.33% | -27.76% | 7.07% | -13.29% | -11.76% | 6.66% | -3.62% |
| May | -8.96% | -9.38% | -0.31% | 1.32% | 8.90% | -6.30% | -2.46% |
| Jun | -7.06% | -4.33% | 15.03% | -1.01% | 5.17% | 35.56% | 7.23% |
| Jul | 0.59% | 26.03% | -3.98% | 12.19% | -16.01% | 0.92% | 3.29% |
| Aug | 2.03% | -20.67% | -6.52% | 8.69% | 2.05% | -13.36% | -4.63% |
| Sep | -13.60% | -5.54% | -1.06% | -13.85% | -9.05% | -0.89% | -7.33% |
| Oct | -8.55% | 17.74% | 6.00% | 9.96% | 13.43% | 7.40%* | 7.66% |
| Nov | -18.83% | -16.59% | 1.54% | 32.17% | 9.66% | -- | 1.59% |
| Dec | 11.65% | 14.27% | -0.03% | -6.52% | -7.24% | -- | 2.43% |
| Total | 22.15% | -37.61% | 34.40% | 86.22% | -24.44% | 11.96% | 15.45% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $41.22
SMA 50: $40.62
SMA 200: $38.66
Current: $42.36
EMA 12: $41.89
EMA 26: $41.33
MACD: 0.5515 | Signal: 0.1915
BULLISH
ADX (14): 13.53
RANGE
+DI: 16.72
−DI: 16.51
Momentum Oscillators
RSI (14): 55.27
NEUTRAL
Stoch %K: 63.17
Stoch %D: 68.61
Williams %R: -34.71
Volume & Volatility
BB Upper: $43.47
BB Lower: $38.97
NEUTRAL
OBV: 9,774,695
Vol SMA 20: 532,775
Vol ROC: -98.88%
ATR: $1.46
True Range: $0.80
HV 20: 36.7%
HV 30: 33.9%
HV 60: 30.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-31T00:00:00 – 2026-10-29T00:00:00
AI Analysis
VCEL (Vericel Corporation) - Comprehensive Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with Confidence Level: 6/10
Investment Thesis: Vericel presents a mixed technical and fundamental picture. While recent earnings (2026-07-30) drove positive sentiment with guidance raises and a share repurchase program, the stock has entered a consolidation phase with deteriorating momentum signals. The stock trades near its 20-day SMA ($40.16) in a range-bound regime (ADX 12.95), suggesting a lack of directional conviction despite positive news catalysts. The low beta (0.76) and defensive volatility profile offer downside protection, but the bearish MACD crossover and elevated IV premium (75.7% above realized volatility) signal caution for new positions.
Key Drivers:
- Q2 2026 earnings beat with guidance raise and $31M repurchase announcement (positive catalyst, July 30)
- Stem cell therapy market tailwinds (11% CAGR through 2034)
- 20% YoY revenue growth momentum
- Insider selling signal: Brown Capital $31M stake reduction (November 2025)
Primary Risks:
- Bearish MACD histogram (-0.18) with signal line crossover suggesting momentum deterioration
- Volume contraction (-48.49% RoC) despite positive news—institutional participation fading
- IV significantly elevated vs. realized volatility—options market pricing elevated risk
- Recent insider selling by major shareholder contradicts bullish guidance narrative
Technical Analysis
Trend Direction
| Timeframe | Direction | Confidence | |-----------|-----------|------------| | Short-term (1-4 weeks) | NEUTRAL/RANGEBOUND | Medium | | Medium-term (1-3 months) | Weakly Bullish | Low | | Long-term (3-12 months) | Bullish | Medium |
Detailed Assessment:
- Current Position: Stock trades $40.37, slightly above SMA 20 ($40.16) but below SMA 50 ($40.93), indicating early-stage consolidation
- Long-term Trend Intact: Price remains well above the 200-day SMA ($38.48, +4.9% below current), confirming the primary uptrend is intact
- Medium-term Softness: Recent pullback below the 50-day MA suggests loss of intermediate momentum; this level (SMA 50: $40.93) will be critical to monitor for trend confirmation
Support/Resistance Levels
| Level | Type | Distance | Significance | |-------|------|----------|--------------| | $39.09 | Support | -3.2% | Lower Bollinger Band; psychological support | | $38.48 | Support | -4.7% | 200-day SMA; major long-term support | | $40.16 | Dynamic Support | -0.5% | 20-day SMA; current consolidation anchor | | $40.93 | Dynamic Resistance | +1.4% | 50-day SMA; needs reclaim for bullish continuation | | $41.24 | Resistance | +2.2% | Upper Bollinger Band; near-term ceiling |
Support/Resistance Interpretation: Strong multi-level support exists from $38.48-$40.16. A breakdown below the 200-day SMA ($38.48) would signal a shift to intermediate-term downtrend and would be the first serious technical deterioration. Conversely, reclaiming the 50-day SMA ($40.93) with volume confirmation could reinitiate the uptrend.
Momentum Signals
RSI (14): 49.64 — NEUTRAL
- Reading is precisely at midpoint, indicating equilibrium between buyers and sellers
- No overbought (>70) or oversold (<30) conditions present
- Suggests minimal reversal risk from momentum extremes
- Position within 30-70 neutral band offers flexibility for directional moves
MACD: -0.07 Signal: 0.11 Histogram: -0.18 — BEARISH DIVERGENCE
- Critical Signal: MACD (-0.07) has crossed BELOW its signal line (0.11), a bearish crossover
- Momentum Deterioration: The negative histogram (-0.18) confirms loss of upside momentum
- Timeline Concern: This crossover likely occurred coincident with or immediately post-earnings (July 30), suggesting momentum peaked around the positive guidance announcement
- Conflict with News: Bullish earnings and raised guidance contradicted by deteriorating technical momentum—classic "buy the news" sell-off scenario
Stochastic %K: 57.95 | %D: 60.75 — NEUTRAL/SLIGHTLY ELEVATED
- Both readings in upper-neutral zone but not yet overbought (>80)
- Slight elevation suggests buying pressure persists, but without extreme conviction
- No divergence warning signals yet
Williams %R: -47.31 — NEUTRAL
- Reading at midpoint of -100 to 0 scale; neither oversold nor overbought
- Confirms balanced supply/demand without extreme positioning
Bollinger Bands Analysis
| Metric | Value | Interpretation | |--------|-------|-----------------| | Width | 5.35 | Moderate; not in squeeze, not extreme expansion | | Position | Middle of bands | Price exactly at 20-day SMA ($40.16) = middle band | | Signal | Neutral | No mean-reversion or breakout imminent |
Band Interpretation: Stock is trading at the midpoint of its Bollinger Bands, indicating neither overbought nor oversold conditions. The moderate band width (5.35) suggests volatility is neither compressed (setting up for breakout) nor elevated (suggesting panic). This reinforces the rangebound, consolidation regime.
Volume Analysis
Critical Concern: Volume Collapse
- Volume Rate of Change: -48.49% — Severe contraction vs. 20-day average
- 20-day Volume SMA: 532,514 — Volume has halved from this baseline
- Signal: Positive earnings news (July 30) failed to attract sustained institutional buying
- Implication: Volume deterioration despite positive catalysts is a red flag for conviction; suggests either profit-taking or institutional disinterest
On-Balance Volume: 9,209,166
- OBV is elevated and trending upward on the longer timeframe, but recent divergence (bullish news + falling volume) is concerning
- Suggests accumulation earlier in the move, but distribution potential if volume remains weak
Institutional Activity Interpretation: The 48.49% volume decline post-earnings is highly unusual for positive catalysts. This suggests:
- Initial retail enthusiasm on July 30 announcement not followed by institutional support
- Possible profit-taking by earlier longs (Brown Capital sale on 11-06 confirms this pattern)
- Risk that buyers are exhausted and sellers are waiting for weakness to reload
News & Sentiment Analysis
Recent Headlines Summary (Last ~12 Months)
| Date | Headline | Sentiment | Significance | |------|----------|-----------|--------------| | 2026-07-30 | Q2 2026 Results, Guidance Raise, $31M Buyback | POSITIVE | Earnings beat; guidance raised—primary bullish catalyst | | 2026-05-05 | Stem Cell Therapy Market 11% CAGR through 2034 | POSITIVE | Sector tailwind; validates industry growth narrative | | 2026-01-13 | Preliminary 2025 FY Results & Business Updates | POSITIVE | Likely included FY guidance reset or strategic updates | | 2025-11-06 | Brown Capital $31M VCEL Stake Reduction | NEUTRAL→BEARISH | Major shareholder exit post-earnings; signals insider lukewarm view | | 2025-08-14 | MediWound Revenue +43% YoY (Q2 2025) | POSITIVE | Subsidiary performance strong; validates business model | | 2025-08-05 | Vericel Q2 2025 Revenue +20% YoY | POSITIVE | Consistent revenue growth; no deceleration signals |
Sentiment Assessment: NET POSITIVE (65%) — TEMPERED BY INSIDER ACTION
Positive Themes:
- Consistent revenue growth (20% YoY in Q2 2025, Q2 2026 metrics suggest continuation)
- Sector tailwinds well-documented (11% market CAG
Generated
News
All VCEL news →
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·9mo ago
The Motley FoolT3·11mo ago
The Motley FoolT3·14mo ago
The Motley FoolT3·15mo ago
GlobeNewswire Inc.T3·27mo ago
GlobeNewswire Inc.T3·27mo ago
Investing.comT3·27mo ago
GlobeNewswire Inc.T3·29mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
20 of 23 under expected move
Avg Expected Move
11.85%
Avg Actual Move
5.29%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | Pre-Market | 5.94% | 3.54% | 0.60x | Within |
| 2021-05-05 | Pre-Market | 5.49% | 4.33% | 0.79x | Within |
| 2021-08-04 | Pre-Market | 6.69% | 4.91% | 0.73x | Within |
| 2021-11-09 | Pre-Market | 14.34% | 2.20% | 0.15x | Within |
| 2022-05-04 | Pre-Market | 14.99% | 0.99% | 0.07x | Within |
| 2022-08-03 | Pre-Market | 3.46% | 0.25% | 0.07x | Within |
| 2022-11-09 | Pre-Market | 9.15% | 23.43% | 2.56x | Exceeded |
| 2023-01-10 | Pre-Market | 20.50% | 16.27% | 0.79x | Within |
| 2023-05-10 | Pre-Market | 9.74% | 4.11% | 0.42x | Within |
| 2023-08-02 | Pre-Market | 10.48% | 1.40% | 0.13x | Within |
| 2023-11-08 | Pre-Market | 14.19% | 3.40% | 0.24x | Within |
| 2024-01-09 | Pre-Market | 7.10% | 7.24% | 1.02x | Exceeded |
| 2024-02-29 | Pre-Market | 12.51% | 4.44% | 0.35x | Within |
| 2024-05-08 | Pre-Market | 11.61% | 3.70% | 0.32x | Within |
| 2024-08-01 | Pre-Market | 10.24% | 5.94% | 0.58x | Within |
| 2024-11-07 | Pre-Market | 19.57% | 4.14% | 0.21x | Within |
| 2025-01-14 | Pre-Market | 9.56% | 1.59% | 0.17x | Within |
| 2025-05-08 | Pre-Market | 12.48% | 3.46% | 0.28x | Within |
| 2025-07-31 | Pre-Market | 13.28% | 14.07% | 1.06x | Exceeded |
| 2025-11-06 | Pre-Market | 17.88% | 4.17% | 0.23x | Within |
| 2026-02-26 | Pre-Market | 17.52% | 1.59% | 0.09x | Within |
| 2026-05-07 | Pre-Market | 10.40% | 4.49% | 0.43x | Within |
| 2026-07-30 | Pre-Market | 15.44% | 2.12% | 0.14x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VCEL Options Activity & IV Rank
VCEL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 68.0%
7-DTE IV: 74.1%
Expected Move: $6.65
7-DTE Move: $6.65
Days to Exp: 21 (2026-11-20)
Options Flow
Call Volume: 12
Put Volume: 4
P/C Volume: 0.333
BULLISH
Call OI: 46
Put OI: 4
P/C OI: 0.087
Total OI: 50
ATM Options Pricing
ATM Call: $4.00
ATM Put: $2.65
Call %: 9.4%
Put %: 6.2%
Chain Summary
Chain Volume: 71
Chain OI: 422
Last Updated: 10/30/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 33rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
33%
vs own history
GEX tilt
+0.55
OI-weighted, today
Vanna tilt
-0.01
δ-sensitivity to IV
Charm tilt
-0.70
δ-decay vs time
Charm tilt -0.70: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)32.7MediumOct 30
IV Rank (30 DTE)75.1HighOct 30
Straddle Price (30 DTE)$6.65Oct 30
Beta Analysis
Risk Metrics
Beta: 0.7049
Alpha: 20.33%
Correlation: 0.2192
R-Squared: 4.8%
Stock Volatility: 40.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own VCEL
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $19.7M | #591 of 1945 | +170.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $611K | #1983 of 4729 | -4.9% | 13F | |
| Citadel Hedge fund Ken Griffin | $393K | #4761 of 6285 | -92.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VCEL Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 51,786,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$2.22M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.07M | 48.39% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $734.09K | 33.13% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $409.31K | 18.47% | 2026-06-30 |
1 filers$444.90K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $444.90K | 100.00% | 2026-06-30 |
VCEL Insider Trading (Form 4)
Latest: 2026-08-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Kevin F McLaughlin | Director | Mixed | — | $28.79 | -$220.4K | EDGAR |
| 2026-08-05 | Michael Halpin | Chief Operating Officer | Mixed | — | $31.75 | -$301.8K | EDGAR |
| 2026-07-31 | Jonathan Siegal | Principal Accounting Officer | Mixed | — | $40.21 | -$78.2K | EDGAR |
| 2026-06-22 | Sean C. Flynn | Chief Legal Officer | Mixed | — | $28.23 | -$359.4K | EDGAR |
| 2026-06-22 | Michael Halpin | Chief Operating Officer | Mixed | — | $28.45 | -$235.8K | EDGAR |
| 2026-06-04 | Jonathan Mark Hopper | Chief Medical Officer | Mixed | — | $25.83 | -$80.2K | EDGAR |
| 2026-05-15 | Kevin F McLaughlin | Director | Mixed | — | $20.33 | -$174.9K | EDGAR |
| 2026-05-13 | Paul K Wotton | Director | Sell (S) | −10,000 | $32.74 | -$327.4K | EDGAR |
| 2026-05-08 | Joseph Anthony Mara Jr | Chief Financial Officer | Sell (S) | −5,000 | $40.50 | -$202.5K | EDGAR |
| 2026-05-08 | Jonathan Siegal | Principal Accounting Officer | Sell (S) | −4,855 | $38.73 | -$188.0K | EDGAR |
| 2026-05-01 | Paul K Wotton | Director | Exer (M) | +3,200 | — | EDGAR | |
| 2026-05-01 | Kevin F McLaughlin | Director | Exer (M) | +3,200 | — | EDGAR | |
| 2026-05-01 | Heidi Hagen | Director | Exer (M) | +3,200 | — | EDGAR | |
| 2026-05-01 | Alan L Rubino | Director | Exer (M) | +3,200 | — | EDGAR | |
| 2026-05-01 | Lisa Wright | Director | Exer (M) | +3,200 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VCEL Insider Holdings
13 insiders · @ $42.36
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Dominick Colangelo | President and CEO | 303,020 | $12.84M | -$35.52M | 55 | 2026-02-26 |
| 2 | Jonathan Mark Hopper | Chief Medical Officer | 80,128 | $3.39M | -$6.26M | 33 | 2026-06-04 |
| 3 | Alan L Rubino | Director | 64,234 | $2.72M | $10.3K | 20 | 2026-05-01 |
| 4 | Heidi Hagen | Director | 35,050 | $1.48M | -$931.9K | 18 | 2026-05-01 |
| 5 | Robert L Md Zerbe | Director | 32,995 | $1.40M | -$1.89M | 29 | 2026-05-01 |
| 6 | Michael Halpin | Chief Operating Officer | 32,753 | $1.39M | -$7.15M | 37 | 2026-08-05 |
| 7 | Joseph Anthony Mara Jr | Chief Financial Officer | 21,009 | $889.9K | -$898.3K | 17 | 2026-05-08 |
| 8 | Paul K Wotton | Director | 18,802 | $796.5K | -$2.63M | 21 | 2026-05-13 |
| 9 | Kevin F McLaughlin | Director | 18,300 | $775.2K | -$2.68M | 22 | 2026-08-14 |
| 10 | Sean C. Flynn | Chief Legal Officer | 16,647 | $705.2K | -$4.97M | 21 | 2026-06-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VCEL Board & Officers
As of SEC filings through Aug 14, 2026Directors 7
- Robert L Md Zerbe · since Jan 16, 2006
- Alan L Rubino · on file since Nov 2006
- Dominick Colangelo · since Mar 6, 2013
- Heidi Hagen · since Aug 23, 2013
- Kevin F McLaughlin · since Jan 6, 2015
- Paul K Wotton · since Jan 6, 2015
- Lisa Wright · since Jun 1, 2021
Officers 7
- Dominick Colangelo · President and CEO · since Mar 6, 2013
- Joseph Anthony Mara Jr · Chief Financial Officer · since Jan 25, 2021
- Michael Halpin · Chief Operating Officer · since Jun 15, 2019
- Jonathan Mark Hopper · Chief Medical Officer · since Feb 11, 2020
- Sean C. Flynn · Chief Legal Officer · listed since Jun 2024
- Karen Mahoney · Chief Human Resources Officer · since Feb 19, 2025
- Jonathan Siegal · Principal Accounting Officer · since Feb 16, 2022
Changes in the last 10 years (11)
| Feb 19, 2025 | Karen Mahoney became Chief Human Resources Officer |
| Jun 24, 2024 | Sean C. Flynn listed as Chief Legal Officer (previously SVP, General Counsel) in SEC filings |
| Feb 13, 2023 | Sean C. Flynn listed as SVP, General Counsel (previously VP, General Counsel) in SEC filings |
| Feb 16, 2022 | Jonathan Siegal became Principal Accounting Officer |
| Jun 1, 2021 | Lisa Wright became a director |
| Jan 25, 2021 | Joseph Anthony Mara Jr became Chief Financial Officer |
| Sep 30, 2020 | Sandra Pennell became VP and Corporate Controller |
| Feb 11, 2020 | Sean C. Flynn became VP, General Counsel |
| Feb 11, 2020 | Jonathan Mark Hopper became Chief Medical Officer |
| Feb 11, 2020 | Daniel Orlando reported in an SEC filing no longer being Chief Operating Officer |
| Jun 15, 2019 | Michael Halpin became Chief Operating Officer |
Not reported recently (3)
- Steven C Gilman · Last reported as a director in an SEC filing dated Oct 18, 2024
- Sandra Pennell · Last reported as VP and Corporate Controller in an SEC filing dated Oct 2, 2020
- Gerard J Michel · Last reported as CFO and VP, Corp. Development in an SEC filing dated Apr 3, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VCEL Proposed Insider Sales (Form 144)
Latest: 2026-08-12
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
3 filings
· $989K notice value
· 3 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Halpin Michael (1, $460K) · MCLAUGHLIN KEVIN F (1, $309K) · SIEGAL JONATHAN (1, $220K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | MCLAUGHLIN KEVIN F | Director | 7,000 | $308.8K | 2026-08-12 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-03 | Halpin Michael | Officer | 10,000 | $459.8K | 2026-08-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-07-30 | SIEGAL JONATHAN | Officer | 4,500 | $220.1K | 2026-07-30 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-26 | Flynn Sean C. | Officer | 15,000 | $684.7K | 2026-06-26 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-26 | Mara Joseph Anthony Jr | Officer | 5,000 | $223.8K | 2026-06-26 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-26 | SIEGAL JONATHAN | Officer | 2,732 | $122.7K | 2026-06-26 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-26 | Hopper Jonathan Mark | Officer | 10,000 | $450.0K | 2026-06-26 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-18 | Flynn Sean C. | Officer | 15,000 | $603.1K | 2026-06-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-18 | Halpin Michael | Officer | 10,000 | $402.4K | 2026-06-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-02 | Hopper Jonathan Mark | Officer | 4,375 | $153.1K | 2026-06-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
78 ETFs hold VCEL
25 shown · $508.52M total exposure · 0.10% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.12% | $126.1M | $106.5B | 2026-10-28 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $65.4M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.07% | $53.7M | $77.1B | 2026-10-28 |
| 4 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.44% | $47.8M | $10.8B | 2026-10-28 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $23.2M | — | 2026-09-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.14% | $19.9M | $14.3B | 2026-10-28 |
| 7 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.12% | $19.2M | $16.0B | 2026-10-28 |
| 8 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.25% | $19.0M | $7.6B | 2026-10-28 |
| 9 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.14% | $16.3M | $11.5B | 2026-10-28 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.04% | $15.2M | — | 2026-10-28 |
| 11 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.07% | $12.0M | — | 2026-09-30 |
| 12 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.25% | $11.9M | $4.7B | 2026-10-28 |
| 13 | PBE Invesco Biotechnology & Genome ETF | Invesco | 2.51% | $11.1M | — | 2026-10-28 |
| 14 | JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF | Janus | 0.95% | $9.9M | $1.1B | 2026-10-28 |
| 15 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.04% | $8.1M | — | 2026-05-31 |
| 16 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.10% | $7.6M | — | 2026-10-28 |
| 17 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.12% | $7.3M | — | 2026-09-30 |
| 18 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $6.2M | — | 2026-10-28 |
| 19 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.09% | $6.2M | $6.8B | 2026-10-28 |
| 20 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.0M | — | 2026-09-30 |
| 21 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.38% | $5.2M | $1.4B | 2026-10-28 |
| 22 | JSML Janus Henderson Small Cap Growth Alpha ETF | Janus | 0.86% | $3.2M | $377.8M | 2026-10-28 |
| 23 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $2.7M | $97.2B | 2026-10-28 |
| 24 | VIOG Vanguard S&P Small-Cap 600 Growth ETF | Vanguard | 0.26% | $2.7M | — | 2026-10-28 |
| 25 | FSMD Fidelity Small-Mid Multifactor ETF | Fidelity | 0.10% | $2.6M | $2.5B | 2026-10-28 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
90.13
TTM Diluted EPS
$0.47
TTM Revenue
$306.30M
TTM Net Income
$24.22M
TTM Op. Cash Flow
$69.67M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $77.46M | $2.21M | $0.04 | $16.19M |
| Q1 '26 | 2026-03-31 | $68.42M | $-6.30M | $-0.12 | $16.38M |
| Q4 '25 | 2025-12-31 | $92.92M | $23.24M | $0.45 | $15.01M |
| Q3 '25 | 2025-09-30 | $67.50M | $5.07M | $0.10 | $22.08M |
| Q2 '25 | 2025-06-30 | $63.24M | $-553.00K | $-0.01 | $8.21M |
| Q1 '25 | 2025-03-31 | $52.60M | $-11.25M | $-0.23 | $6.60M |
| Q4 '24 | 2024-12-31 | $75.38M | $19.81M | $0.39 | $22.24M |
| Q3 '24 | 2024-09-30 | $57.91M | $-901.00K | $-0.02 | $10.18M |
| Q2 '24 | 2024-06-30 | $52.66M | $-4.68M | $-0.10 | $18.54M |
| Q1 '24 | 2024-03-31 | $51.28M | $-3.86M | $-0.08 | $7.20M |
| Q4 '23 | 2023-12-31 | $65.00M | $12.99M | $0.27 | $10.09M |
| Q3 '23 | 2023-09-30 | $45.58M | $-3.66M | $-0.08 | $7.17M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
90.13
P/B
5.93
P/S
7.16
EV/EBITDA
66.39
EV/Sales
6.75
ROE
6.5%
ROA
4.8%
Div Yield
0.00%
FCF Yield
3.18%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.19B
as of 2026-10-30
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.20M
SI % of Float
11.00%
Days to Cover
9.64
Short Vol Ratio
64.4%
Free Float
47.31M
Float %
92.4%
Short interest 2026-09-30 • Short volume 2026-10-29 • Float 2026-08-07